Edward Jacobs
DPhil student at the University of Oxford’s Department of Psychiatry
Data updated
Research Footprint
Edward Jacobs appears in 5 tracked papers (2020–2026), most studied alongside Psilocybin and MDMA, across Safety & Risk Management, Substance Use Disorders (SUD) and Depressive Disorders.
Most-cited paper: Psychedelics as potential catalysts of scientific creativity and insight (24 citations).
Frequent co-authors: David Yaden, David Luke and Sandeep Nayak.
Background & Research
Edward Jacobs is a researcher at the University of Oxford’s Department of Psychiatry, where his work focuses on the ethical dimensions of psychedelic-assisted psychotherapy. He has been involved in the Hopkins-Oxford Psychedelic Ethics (HOPE) Working Group and has coauthored papers on psychedelic ethics, post-trial obligations, and clinical translation.
Key Impact
He is a bioethics-focused psychedelic researcher who has coauthored influential work on ethics, post-trial access, and clinical translation in psychedelic medicine.
Collaboration Network
20 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Edward Jacobs is associated with.
University of Oxford Department of Psychiatry
The Department of Psychiatry at the University of Oxford is a clinical department within the Medical Sciences Division that conducts research, teaching, and clinical trials across psychiatry, neuroscience, and mental health. It is based at the Warneford Hospital site in Oxford, England.
View stakeholder →Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →